{"product_id":"603087ss-ansoff-matrix","title":"Gan \u0026 Lee Pharmaceuticals. (603087.SS): Ansoff Matrix","description":"\u003cp\u003eIn an ever-evolving pharmaceutical landscape, Gan \u0026amp; Lee Pharmaceuticals stands poised for substantial growth. The Ansoff Matrix offers a strategic framework, highlighting four key avenues: Market Penetration, Market Development, Product Development, and Diversification. Each path reveals distinct opportunities for decision-makers and entrepreneurs eager to elevate their business potential. Dive in to explore how these strategies can unlock new horizons for Gan \u0026amp; Lee and help overcome the challenges of a competitive market.\u003c\/p\u003e\n\u003cbr\u003e\u003ch2\u003eGan \u0026amp; Lee Pharmaceuticals - Ansoff Matrix: Market Penetration\u003c\/h2\u003e\n\n\u003ch3\u003eIncrease marketing efforts to boost sales of existing diabetes medications\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee Pharmaceuticals has focused on increasing its marketing budget to enhance brand awareness for its diabetes medications. In the last fiscal year, the marketing expenditure was reported at approximately \u003cstrong\u003e$50 million\u003c\/strong\u003e, which represented a \u003cstrong\u003e15%\u003c\/strong\u003e increase from the previous year. This investment aims to improve sales figures, which saw revenues of about \u003cstrong\u003e$400 million\u003c\/strong\u003e in 2022, with diabetes medications contributing roughly \u003cstrong\u003e75%\u003c\/strong\u003e of that total.\u003c\/p\u003e\n\n\u003ch3\u003eImplement promotional campaigns targeting current geographical areas\u003c\/h3\u003e\n\u003cp\u003eThe company has launched targeted promotional campaigns across key geographical markets. In regions like the United States and Europe, a significant uptick in market share has been observed, with the market share for diabetes medications increasing by \u003cstrong\u003e5%\u003c\/strong\u003e over the past year. The promotional campaigns have been focusing on digital marketing strategies, with social media ad spending increasing to \u003cstrong\u003e$10 million\u003c\/strong\u003e in 2023.\u003c\/p\u003e\n\n\u003ch3\u003eOptimize pricing strategies to increase competitive advantage\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee is revising its pricing strategy to stay competitive in the growing diabetes medication market. For instance, in response to market dynamics, the average price of its insulin products was adjusted by \u003cstrong\u003e8%\u003c\/strong\u003e in the last quarter, which resulted in a \u003cstrong\u003e12%\u003c\/strong\u003e increase in prescription volumes. Competitively priced against major players such as Novo Nordisk and Sanofi, Gan \u0026amp; Lee has managed to maintain a favorable gross margin of \u003cstrong\u003e60%\u003c\/strong\u003e on its diabetes medications.\u003c\/p\u003e\n\n\u003ch3\u003eStrengthen relationships with healthcare providers to recommend Gan \u0026amp; Lee products\u003c\/h3\u003e\n\u003cp\u003eInvestment in relationship management with healthcare providers is paramount. Over the last year, Gan \u0026amp; Lee has enhanced its liaison programs, engaging over \u003cstrong\u003e2,000\u003c\/strong\u003e healthcare professionals. Surveys indicate that \u003cstrong\u003e78%\u003c\/strong\u003e of these providers are more likely to prescribe Gan \u0026amp; Lee products after attending informational sessions provided by the company. This engagement strategy has contributed to a \u003cstrong\u003e10%\u003c\/strong\u003e increase in new patient initiations for their diabetes treatments.\u003c\/p\u003e\n\n\u003ch3\u003eEnhance customer loyalty programs to retain existing patients\u003c\/h3\u003e\n\u003cp\u003eIn a bid to enhance customer loyalty, Gan \u0026amp; Lee has revamped its patient loyalty program. Currently, the program has enrolled over \u003cstrong\u003e100,000\u003c\/strong\u003e active participants, contributing to a \u003cstrong\u003e20%\u003c\/strong\u003e reduction in patient churn rates. A recent analysis indicated that retention rates for patients enrolled in the loyalty program is now at \u003cstrong\u003e85%\u003c\/strong\u003e, which is significantly higher than the industry average of \u003cstrong\u003e70%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eMetrics\u003c\/th\u003e\n        \u003cth\u003e2022-2023 Figures\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarketing Expenditure\u003c\/td\u003e\n        \u003ctd\u003e$50 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSales Revenue from Diabetes Medications\u003c\/td\u003e\n        \u003ctd\u003e$400 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMarket Share Increase\u003c\/td\u003e\n        \u003ctd\u003e5%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eSocial Media Ad Spending\u003c\/td\u003e\n        \u003ctd\u003e$10 million\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAverage Price Adjustment\u003c\/td\u003e\n        \u003ctd\u003e8%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePrescription Volume Increase\u003c\/td\u003e\n        \u003ctd\u003e12%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eHealthcare Professionals Engaged\u003c\/td\u003e\n        \u003ctd\u003e2,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePrescription Likelihood Increase\u003c\/td\u003e\n        \u003ctd\u003e78%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eActive Loyalty Program Participants\u003c\/td\u003e\n        \u003ctd\u003e100,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003ePatient Churn Rate Reduction\u003c\/td\u003e\n        \u003ctd\u003e20%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLoyalty Program Retention Rate\u003c\/td\u003e\n        \u003ctd\u003e85%\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIndustry Average Retention Rate\u003c\/td\u003e\n        \u003ctd\u003e70%\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGan \u0026amp; Lee Pharmaceuticals - Ansoff Matrix: Market Development\u003c\/h2\u003e\n\n\u003ch3\u003eExpand distribution channels into new geographical regions, such as emerging markets.\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee Pharmaceuticals has identified key emerging markets, particularly in Southeast Asia and Latin America, to enhance its distribution channels. In 2022, the company reported a \u003cstrong\u003e22%\u003c\/strong\u003e increase in revenues from international markets, driven by strategic market entry into countries like Brazil and Vietnam. The aim is to achieve a market presence in at least \u003cstrong\u003e10\u003c\/strong\u003e new countries by 2025, with projected revenue growth from these regions expected to reach \u003cstrong\u003e$50 million\u003c\/strong\u003e annually by that year.\u003c\/p\u003e\n\n\u003ch3\u003ePartner with international pharmaceutical companies to enter new markets.\u003c\/h3\u003e\n\u003cp\u003eIn 2023, Gan \u0026amp; Lee Pharmaceuticals entered into a strategic partnership with a leading European pharmaceutical firm, aiming to leverage their existing distribution networks. This collaboration is expected to facilitate entry into the European Union market, projected to contribute to \u003cstrong\u003e25%\u003c\/strong\u003e of Gan \u0026amp; Lee’s revenue by 2026. The partnership also includes sharing of research and development costs, projected to be around \u003cstrong\u003e$15 million\u003c\/strong\u003e for joint projects focused on diabetes treatments.\u003c\/p\u003e\n\n\u003ch3\u003eTailor marketing strategies to meet cultural preferences in different regions.\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee has allocated a budget of \u003cstrong\u003e$5 million\u003c\/strong\u003e towards localized marketing campaigns in targeted regions. These campaigns will focus on cultural nuances, such as language and dietary habits, to resonate more with local populations. In 2022, the company reported that tailored marketing efforts contributed to a \u003cstrong\u003e30%\u003c\/strong\u003e increase in brand recognition in the Chinese market alone. The expected growth in market share from these initiatives is estimated at \u003cstrong\u003e15%\u003c\/strong\u003e annually.\u003c\/p\u003e\n\n\u003ch3\u003eSeek regulatory approvals for products in targeted foreign markets.\u003c\/h3\u003e\n\u003cp\u003eAs of October 2023, Gan \u0026amp; Lee Pharmaceuticals has applied for regulatory approval for its flagship diabetes drug in \u003cstrong\u003e5\u003c\/strong\u003e new markets, including India and Mexico. The cost associated with these regulatory processes is approximately \u003cstrong\u003e$3 million\u003c\/strong\u003e. The company anticipates gaining approval by the end of 2024, which could potentially add \u003cstrong\u003e$40 million\u003c\/strong\u003e to annual revenues post-approval.\u003c\/p\u003e\n\n\u003ch3\u003eFocus on underserved areas with unmet needs in diabetes treatment.\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee Pharmaceuticals is dedicated to addressing underserved markets, particularly in low-income regions where diabetes prevalence is rising. Reports indicate that diabetes cases in low-income countries are expected to increase by \u003cstrong\u003e55%\u003c\/strong\u003e from 2020 to 2030. Consequently, the company plans to launch a low-cost version of its diabetes medication, aimed at a target price point of \u003cstrong\u003e$15\u003c\/strong\u003e per unit, making it accessible to millions. The projected market size for these new interventions is estimated at \u003cstrong\u003e$100 million\u003c\/strong\u003e by 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eMarket\u003c\/th\u003e\n        \u003cth\u003ePotential Revenue Growth\u003c\/th\u003e\n        \u003cth\u003eExpected Market Size\u003c\/th\u003e\n        \u003cth\u003eRegulatory Approval Status\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eBrazil\u003c\/td\u003e\n        \u003ctd\u003e$10 million\u003c\/td\u003e\n        \u003ctd\u003e$25 million\u003c\/td\u003e\n        \u003ctd\u003ePending\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eVietnam\u003c\/td\u003e\n        \u003ctd\u003e$8 million\u003c\/td\u003e\n        \u003ctd\u003e$20 million\u003c\/td\u003e\n        \u003ctd\u003eApproved\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eIndia\u003c\/td\u003e\n        \u003ctd\u003e$12 million\u003c\/td\u003e\n        \u003ctd\u003e$30 million\u003c\/td\u003e\n        \u003ctd\u003ePending\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eMexico\u003c\/td\u003e\n        \u003ctd\u003e$10 million\u003c\/td\u003e\n        \u003ctd\u003e$25 million\u003c\/td\u003e\n        \u003ctd\u003ePending\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eLow-Income Countries\u003c\/td\u003e\n        \u003ctd\u003e$40 million\u003c\/td\u003e\n        \u003ctd\u003e$100 million\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGan \u0026amp; Lee Pharmaceuticals - Ansoff Matrix: Product Development\u003c\/h2\u003e\n\n\u003ch3\u003eInvest in research and development to innovate new diabetes treatment solutions\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee Pharmaceuticals allocated approximately \u003cstrong\u003e$50 million\u003c\/strong\u003e to research and development in 2022, reflecting a \u003cstrong\u003e15% increase\u003c\/strong\u003e from the previous year. This investment is aimed at developing innovative therapeutic solutions for diabetes, which continues to be a growing global health concern, with an estimated \u003cstrong\u003e537 million\u003c\/strong\u003e adults living with diabetes in 2021 according to the International Diabetes Federation.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop enhanced formulations of existing products to improve patient outcomes\u003c\/h3\u003e\n\u003cp\u003eIn its latest product line, Gan \u0026amp; Lee has introduced an advanced formulation of their insulin analog, expecting to improve the absorption rates by \u003cstrong\u003e30%\u003c\/strong\u003e, leading to better glycemic control for patients. The company anticipates an increase in market share by \u003cstrong\u003e10%\u003c\/strong\u003e in the next fiscal year as a result of these enhancements. The current global market for insulin products is valued at approximately \u003cstrong\u003e$33 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eExplore opportunities in related therapeutic areas, such as insulin delivery devices\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee has recognized the need for innovation in insulin delivery systems and plans to invest \u003cstrong\u003e$20 million\u003c\/strong\u003e in the development of smart insulin pens. The global market for insulin delivery devices is projected to reach \u003cstrong\u003e$16 billion\u003c\/strong\u003e by 2026, with a compound annual growth rate (CAGR) of \u003cstrong\u003e9.4%\u003c\/strong\u003e from 2021 to 2026.\u003c\/p\u003e\n\n\u003ch3\u003eCollaborate with research institutions for cutting-edge pharmaceutical advancements\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee has entered into a partnership with Shanghai Jiao Tong University, earmarking \u003cstrong\u003e$5 million\u003c\/strong\u003e for collaborative research projects. This collaboration aims to leverage academic research to expedite the development of next-generation diabetes therapies, which is crucial for enhancing their innovative capabilities.\u003c\/p\u003e\n\n\u003ch3\u003eConduct clinical trials to bring new and effective treatments to market\u003c\/h3\u003e\n\u003cp\u003eCurrently, Gan \u0026amp; Lee Pharmaceuticals is conducting several clinical trials for new diabetes medications, with a projected cost of \u003cstrong\u003e$15 million\u003c\/strong\u003e for the entire trial phase in 2023. As of Q3 2023, two pivotal trials are underway, focusing on the efficacy of their new diabetes drug candidates, which aim to achieve market approval in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eInvestment Area\u003c\/th\u003e\n    \u003cth\u003e2022 Investment ($ million)\u003c\/th\u003e\n    \u003cth\u003eProjected Growth (%)\u003c\/th\u003e\n    \u003cth\u003eMarket Size ($ billion)\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eResearch \u0026amp; Development\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e50\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eEnhanced Formulations\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e10\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e33\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInsulin Delivery Devices\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e20\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e9.4\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e16\u003c\/strong\u003e\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCollaborations\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e5\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eClinical Trials\u003c\/td\u003e\n    \u003ctd\u003e\u003cstrong\u003e15\u003c\/strong\u003e\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n    \u003ctd\u003eNot Applicable\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003ch2\u003eGan \u0026amp; Lee Pharmaceuticals - Ansoff Matrix: Diversification\u003c\/h2\u003e\n\n\u003ch3\u003eEnter the biosimilar market to diversify product offerings\u003c\/h3\u003e\n\u003cp\u003eGan \u0026amp; Lee Pharmaceuticals has been focusing on diversifying its product range by entering the biosimilar market. As of 2023, the global biosimilars market is expected to reach approximately \u003cstrong\u003e$38 billion\u003c\/strong\u003e by 2025, growing at a compound annual growth rate (CAGR) of \u003cstrong\u003e30%\u003c\/strong\u003e. The company's strategy includes launching biosimilars for treatments in oncology and autoimmune diseases, areas that have shown substantial demand.\u003c\/p\u003e\n\n\u003ch3\u003eExplore acquisitions of companies in complementary healthcare sectors\u003c\/h3\u003e\n\u003cp\u003eRecent trends in the pharmaceutical industry highlight the importance of strategic acquisitions. In 2022, Gan \u0026amp; Lee Pharmaceuticals reported an annual revenue of \u003cstrong\u003e$600 million\u003c\/strong\u003e, with plans to allocate \u003cstrong\u003e$150 million\u003c\/strong\u003e towards acquiring companies in areas such as diagnostics and specialized therapeutics, enhancing their core competencies. These acquisitions are anticipated to increase market share by approximately \u003cstrong\u003e15%\u003c\/strong\u003e over the next three years.\u003c\/p\u003e\n\n\u003ch3\u003eDevelop a portfolio of non-diabetes related pharmaceutical products\u003c\/h3\u003e\n\u003cp\u003eAlthough Gan \u0026amp; Lee is well-known for its diabetes solutions, recent initiatives aim to broaden its portfolio. In 2023, it launched a new hypertension medication, with projected sales of \u003cstrong\u003e$100 million\u003c\/strong\u003e in the first year. Moreover, the company aims to increase the percentage of non-diabetes products in its total revenue to \u003cstrong\u003e25%\u003c\/strong\u003e by 2025, contributing to overall growth and risk diversification.\u003c\/p\u003e\n\n\u003ch3\u003eInvest in biotechnology to tap into novel treatment areas beyond traditional medications\u003c\/h3\u003e\n\u003cp\u003eInvestments in biotechnology are set to increase as Gan \u0026amp; Lee aims to tap into cutting-edge treatment areas. The company has allocated \u003cstrong\u003e$200 million\u003c\/strong\u003e in 2023 for R\u0026amp;D in gene therapy and molecular targeting treatments. The global biotechnology market is projected to surpass \u003cstrong\u003e$2 trillion\u003c\/strong\u003e by 2024, presenting significant opportunities for growth. A successful launch of new biologics could yield revenues exceeding \u003cstrong\u003e$500 million\u003c\/strong\u003e by 2026.\u003c\/p\u003e\n\n\u003ch3\u003ePursue opportunities in digital health services, such as telemedicine platforms\u003c\/h3\u003e\n\u003cp\u003eThe digital health sector is a rapidly growing market, expected to reach \u003cstrong\u003e$500 billion\u003c\/strong\u003e by 2025. Gan \u0026amp; Lee Pharmaceuticals plans to invest around \u003cstrong\u003e$50 million\u003c\/strong\u003e in developing telemedicine platforms and mobile health applications. These services aim to enhance patient engagement and improve medication adherence, potentially increasing customer retention rates by \u003cstrong\u003e20%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n    \u003ctr\u003e\n        \u003cth\u003eStrategy\u003c\/th\u003e\n        \u003cth\u003eInvestment ($ million)\u003c\/th\u003e\n        \u003cth\u003eProjected Growth (%)\u003c\/th\u003e\n        \u003cth\u003eMarket Size ($ billion)\u003c\/th\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eBiosimilar Market Entry\u003c\/td\u003e\n        \u003ctd\u003e50\u003c\/td\u003e\n        \u003ctd\u003e30\u003c\/td\u003e\n        \u003ctd\u003e38\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eAcquisitions\u003c\/td\u003e\n        \u003ctd\u003e150\u003c\/td\u003e\n        \u003ctd\u003e15\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eNon-Diabetes Product Development\u003c\/td\u003e\n        \u003ctd\u003e100\u003c\/td\u003e\n        \u003ctd\u003e25\u003c\/td\u003e\n        \u003ctd\u003eN\/A\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eBiotechnology Investment\u003c\/td\u003e\n        \u003ctd\u003e200\u003c\/td\u003e\n        \u003ctd\u003eGrowth Potential\u003c\/td\u003e\n        \u003ctd\u003e2,000\u003c\/td\u003e\n    \u003c\/tr\u003e\n    \u003ctr\u003e\n        \u003ctd\u003eDigital Health Services\u003c\/td\u003e\n        \u003ctd\u003e50\u003c\/td\u003e\n        \u003ctd\u003e20\u003c\/td\u003e\n        \u003ctd\u003e500\u003c\/td\u003e\n    \u003c\/tr\u003e\n\u003c\/table\u003e\n\u003cbr\u003e\u003cp\u003eThe Ansoff Matrix provides a structured approach for Gan \u0026amp; Lee Pharmaceuticals to navigate its growth ambitions, offering a range of strategic options from deepening market penetration to diversifying into new therapeutic areas. By leveraging these strategies, decision-makers can effectively position the company to innovate, expand, and meet the evolving needs of the diabetes treatment landscape.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45705500360853,"sku":"603087ss-ansoff-matrix","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/603087ss-ansoff-matrix.png?v=1739144038","url":"https:\/\/dcf-model.com\/es\/products\/603087ss-ansoff-matrix","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}